Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT04006418
Recruiting Observational

A Registered Cohort Study on Spastic Paraplegia

NCT04006418 · tracked via the Priya Life Science China tracker
Sponsor
Wan-Jin Chen
Phase
Observational
Started
2019-07-01
Last updated
2022-01-19

Condition(s) studied

Spastic Paraplegia

Study summary

The aim of this study is to determine the clinical spectrum and natural progression of Hereditary Spastic Paraplegias(HSP) and related disorders in a prospective multicenter natural history study, to assess the clinical, genetic and epigenetic features of patients with Spastic Paraplegias to optimize clinicalmanagement..

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Patients with the clinical diagnosis of spastic paraplegia * Clinical diagnosis of patients with spastic paraplegia * Unrelated healthy controls Exclusion Criteria: * Decline to participate. * There are serious interferences with individual participation and adherence to the research protocol, including but not limited to neurological, psychological, and/or medical conditions.

Primary outcome measure(s)

  • Spastic Paraplegia Rating Scale (SPRS) — 6 months
    Disease severity will be assessed by application of the Spastic Paraplegia Rating Scale (SPRS), a clinical rating scale measuring disease severity in Hereditary Spastic Paraplegia (Schule et al. Neurology 2006). The SPRS contains 13 items, each ranging from 0 to 4 points. The total score is calculated as the sum of all items, yielding a range for the total score between 0 and 52. Hereby, higher SPRS total scores indicate more severe disease.

Trial sites (1)

FacilityCityRegionStatus
First Affiliated Hospital Fujian Medical University Fuzhou China Recruiting

More Wan-Jin Chen trials in China

A Registered Cohort Study on Wilson's Disease Recruiting
A Registered Cohort Study on Brain Calcification Recruiting
Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke Active, not recruiting
A Registered Cohort Study on SMA Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04006418 on ClinicalTrials.gov ↗ ← All trials in China